Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBM588 + Cabozantinib/Nivolumab in Metastatic Renal Cell Carcinoma
NCT05122546Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Nov 2021
- Primary completion
- Jan 2027
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of clostridium butyricum in renal cell carcinoma (RCC) (2 arms), sponsored by City of Hope. Primary endpoint: Change in Bifidobacterium composition of stool at 12 weeks. Started Nov 2021; status: active, not recruiting.
02
Drugs
clostridium butyricum
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05122546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05122546.